JP2012528240A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012528240A5 JP2012528240A5 JP2012513256A JP2012513256A JP2012528240A5 JP 2012528240 A5 JP2012528240 A5 JP 2012528240A5 JP 2012513256 A JP2012513256 A JP 2012513256A JP 2012513256 A JP2012513256 A JP 2012513256A JP 2012528240 A5 JP2012528240 A5 JP 2012528240A5
- Authority
- JP
- Japan
- Prior art keywords
- phf
- conjugate
- gly
- cpt
- conjugate according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940127093 camptothecin Drugs 0.000 claims description 46
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 28
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 27
- 229940079593 drug Drugs 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 25
- 125000005647 linker group Chemical group 0.000 claims description 20
- 229910052757 nitrogen Inorganic materials 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 20
- 125000004429 atom Chemical group 0.000 claims description 19
- 125000000217 alkyl group Chemical group 0.000 claims description 18
- 125000001142 dicarboxylic acid group Chemical group 0.000 claims description 18
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 16
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims description 14
- 150000001413 amino acids Chemical class 0.000 claims description 14
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 14
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 14
- 229930182556 Polyacetal Natural products 0.000 claims description 13
- 229920001855 polyketal Polymers 0.000 claims description 13
- 229920006324 polyoxymethylene Polymers 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 229940122803 Vinca alkaloid Drugs 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 12
- 125000001072 heteroaryl group Chemical group 0.000 claims description 10
- 125000000623 heterocyclic group Chemical group 0.000 claims description 10
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 claims description 8
- 150000002148 esters Chemical class 0.000 claims description 8
- 125000005842 heteroatom Chemical group 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 210000000214 mouth Anatomy 0.000 claims description 8
- 210000003739 neck Anatomy 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 229960001592 paclitaxel Drugs 0.000 claims description 5
- 206010003571 Astrocytoma Diseases 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 206010027406 Mesothelioma Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 206010039491 Sarcoma Diseases 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 125000001931 aliphatic group Chemical group 0.000 claims description 4
- 150000003797 alkaloid derivatives Chemical class 0.000 claims description 4
- 210000000436 anus Anatomy 0.000 claims description 4
- 210000000481 breast Anatomy 0.000 claims description 4
- 210000001072 colon Anatomy 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 210000003238 esophagus Anatomy 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 210000001508 eye Anatomy 0.000 claims description 4
- 210000003128 head Anatomy 0.000 claims description 4
- 201000011066 hemangioma Diseases 0.000 claims description 4
- 210000003734 kidney Anatomy 0.000 claims description 4
- 210000000867 larynx Anatomy 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 210000004185 liver Anatomy 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
- 150000002894 organic compounds Chemical class 0.000 claims description 4
- 210000001672 ovary Anatomy 0.000 claims description 4
- 210000000496 pancreas Anatomy 0.000 claims description 4
- 210000003800 pharynx Anatomy 0.000 claims description 4
- 239000008363 phosphate buffer Substances 0.000 claims description 4
- 210000002307 prostate Anatomy 0.000 claims description 4
- 210000000664 rectum Anatomy 0.000 claims description 4
- 210000002784 stomach Anatomy 0.000 claims description 4
- 210000001550 testis Anatomy 0.000 claims description 4
- 210000003932 urinary bladder Anatomy 0.000 claims description 4
- 210000004291 uterus Anatomy 0.000 claims description 4
- IICQZTQZQSBHBY-HWKANZROSA-N (e)-non-2-ene Chemical compound CCCCCC\C=C\C IICQZTQZQSBHBY-HWKANZROSA-N 0.000 claims description 3
- IICQZTQZQSBHBY-UHFFFAOYSA-N 2t-nonene Natural products CCCCCCC=CC IICQZTQZQSBHBY-UHFFFAOYSA-N 0.000 claims description 3
- CEVCTNCUIVEQOY-UHFFFAOYSA-N Fumagillol Natural products O1C(CC=C(C)C)C1(C)C1C(OC)C(O)CCC21CO2 CEVCTNCUIVEQOY-UHFFFAOYSA-N 0.000 claims description 2
- 150000001414 amino alcohols Chemical class 0.000 claims description 2
- 125000005365 aminothiol group Chemical class 0.000 claims description 2
- 230000001588 bifunctional effect Effects 0.000 claims description 2
- 150000004985 diamines Chemical class 0.000 claims description 2
- CEVCTNCUIVEQOY-STXHBLNNSA-N fumagillol Chemical compound C([C@@H](O)[C@H](C1[C@]2(C)[C@H](O2)CC=C(C)C)OC)C[C@@]21CO2 CEVCTNCUIVEQOY-STXHBLNNSA-N 0.000 claims description 2
- 239000000178 monomer Substances 0.000 claims description 2
- 150000003335 secondary amines Chemical class 0.000 claims description 2
- 150000003512 tertiary amines Chemical class 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 9
- 229920001307 poly(hydroxymethylethylene hydroxymethyl formal) Polymers 0.000 claims 5
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- 125000000524 functional group Chemical group 0.000 claims 2
- -1 2-nonen-2-yl Chemical group 0.000 claims 1
- 229930190064 illudin Natural products 0.000 claims 1
- 238000000034 method Methods 0.000 description 10
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 description 2
- 239000000872 buffer Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18192609P | 2009-05-28 | 2009-05-28 | |
| US61/181,926 | 2009-05-28 | ||
| PCT/US2010/036413 WO2010138719A1 (en) | 2009-05-28 | 2010-05-27 | Polyal drug conjugates comprising variable rate-releasing linkers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012528240A JP2012528240A (ja) | 2012-11-12 |
| JP2012528240A5 true JP2012528240A5 (enExample) | 2013-05-30 |
Family
ID=43220947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012513256A Pending JP2012528240A (ja) | 2009-05-28 | 2010-05-27 | 可変速度放出リンカーを含むポリアル−薬物コンジュゲート |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8524214B2 (enExample) |
| EP (1) | EP2435053B1 (enExample) |
| JP (1) | JP2012528240A (enExample) |
| KR (1) | KR20120057588A (enExample) |
| CN (1) | CN102448469A (enExample) |
| AR (1) | AR078510A1 (enExample) |
| AU (1) | AU2010254013A1 (enExample) |
| CA (1) | CA2762877A1 (enExample) |
| IL (1) | IL216325A0 (enExample) |
| TW (1) | TW201102089A (enExample) |
| WO (1) | WO2010138719A1 (enExample) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0820229A2 (pt) * | 2007-11-28 | 2017-05-09 | A Stevenson Cheri | conjugados de análogos de fumagilina biodegradáveis biocompatíveis |
| US8349308B2 (en) * | 2010-03-26 | 2013-01-08 | Mersana Therapeutics, Inc. | Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof |
| WO2012092339A2 (en) * | 2010-12-28 | 2012-07-05 | The Children's Hospital Of Philadelphia | The design of hydrolytically releasable prodrugs for sustained release nanoparticle formulations |
| EP2717916B1 (en) | 2011-06-10 | 2017-03-08 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| ES2697674T3 (es) | 2011-11-01 | 2019-01-25 | Bionomics Inc | Procedimientos para bloquear el crecimiento de células madre cancerosas |
| WO2013096901A1 (en) * | 2011-12-23 | 2013-06-27 | Mersana Therapeutics, Inc. | Pharmaceutical formulations for fumagillin derivative-phf conjugates |
| WO2014093394A1 (en) | 2012-12-10 | 2014-06-19 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| US10226535B2 (en) | 2012-12-10 | 2019-03-12 | Mersana Therapeutics, Inc. | Auristatin compounds and conjugates thereof |
| US9872918B2 (en) | 2012-12-12 | 2018-01-23 | Mersana Therapeutics, Inc. | Hydroxyl-polymer-drug-protein conjugates |
| HK1220626A1 (zh) | 2013-03-15 | 2017-05-12 | The Centre For Drug Research And Development | 具细胞毒性和抗有丝分裂的化合物以及其使用方法 |
| CN106061483B (zh) | 2013-10-04 | 2021-01-08 | 普洛林克斯有限责任公司 | Sn-38的缓释结合物 |
| WO2015054659A1 (en) | 2013-10-11 | 2015-04-16 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| CA2927022C (en) | 2013-10-11 | 2018-08-21 | Asana Biosciences, Llc | Protein-polymer-drug conjugates |
| KR102384740B1 (ko) | 2013-12-27 | 2022-04-07 | 자임워크스 인코포레이티드 | 약물 접합체를 위한 설폰아마이드-함유 연결 시스템 |
| ES2905569T3 (es) | 2014-09-17 | 2022-04-11 | Zymeworks Inc | Compuestos citotóxicos y antimitóticos y métodos para utilizarlos |
| CA2966005C (en) | 2014-10-31 | 2021-04-27 | Abbvie Biotherapeutics Inc. | Anti-cs1 antibodies and antibody drug conjugates |
| MX2017006167A (es) | 2014-11-12 | 2018-03-23 | Siamab Therapeutics Inc | Compuestos que interactúan con glicanos y métodos de uso. |
| RU2017123942A (ru) | 2014-12-09 | 2019-01-11 | Эббви Инк. | Ингибирующие bcl-xl соединения, обладающие низкой клеточной проницаемостью, и коньюгаты антитело-лекарственное средство, включающие их |
| EP3229844B1 (en) | 2014-12-09 | 2020-03-04 | AbbVie Inc. | Antibody drug conjugates with cell permeable bcl-xl inhibitors |
| JP2019500011A (ja) | 2015-11-03 | 2019-01-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 腫瘍選択性及び阻害性が増強された二重特異性抗体及びその使用 |
| CA3002097A1 (en) | 2015-11-12 | 2017-05-18 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| EP3383909B1 (en) | 2015-11-30 | 2020-06-17 | AbbVie Inc. | Anti-human lrrc15 antibody drug conjugates and methods for their use |
| JP2019501124A (ja) | 2015-11-30 | 2019-01-17 | アッヴィ・インコーポレイテッド | 抗ｈｕＬＲＲＣ１５抗体薬物コンジュゲート及びその使用方法 |
| US10745487B2 (en) | 2016-03-22 | 2020-08-18 | Bionomics Limited | Method of treating cancer by administering an anti-LGR5 monoclonal antibody |
| RS61659B1 (sr) | 2016-05-17 | 2021-04-29 | Abbvie Biotherapeutics Inc | Konjugati antitelo lek anti-cmet i metode za njihovu upotrebu |
| EP3464400B1 (en) * | 2016-06-03 | 2022-04-06 | Novacyte Therapeutics Company.,LTD | Polymer linkers and their uses |
| WO2017214456A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
| CN109562190A (zh) | 2016-06-08 | 2019-04-02 | 艾伯维公司 | 抗egfr抗体药物偶联物 |
| MX2018015272A (es) | 2016-06-08 | 2019-08-12 | Abbvie Inc | Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco. |
| MX2018015284A (es) | 2016-06-08 | 2019-09-18 | Abbvie Inc | Conjugados de anticuerpo anti-egfr y fármaco. |
| CN116059201A (zh) | 2016-06-08 | 2023-05-05 | 艾伯维公司 | 抗egfr抗体药物偶联物 |
| CN109641962A (zh) | 2016-06-08 | 2019-04-16 | 艾伯维公司 | 抗b7-h3抗体和抗体药物偶联物 |
| MX2018015268A (es) | 2016-06-08 | 2019-08-12 | Abbvie Inc | Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco. |
| JP2019526529A (ja) | 2016-06-08 | 2019-09-19 | アッヴィ・インコーポレイテッド | 抗ｂ７−ｈ３抗体及び抗体薬物コンジュゲート |
| RS61828B1 (sr) | 2016-06-08 | 2021-06-30 | Abbvie Inc | Anti-b7-h3 antitela i antitelske konjugacije lekova |
| US11617799B2 (en) | 2016-06-27 | 2023-04-04 | Tagworks Pharmaceuticals B.V. | Cleavable tetrazine used in bio-orthogonal drug activation |
| LT3512882T (lt) | 2016-09-14 | 2021-06-25 | Merck Patent Gmbh | Anti-c-met antikūnai ir jų antikūno-vaisto konjugatai, skirti efektyviam naviko slopinimui |
| DK3529269T3 (da) | 2016-10-19 | 2026-02-23 | Invenra Inc | Antistof-konstruktioner |
| WO2018094143A1 (en) | 2016-11-17 | 2018-05-24 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| US11135307B2 (en) | 2016-11-23 | 2021-10-05 | Mersana Therapeutics, Inc. | Peptide-containing linkers for antibody-drug conjugates |
| WO2018115485A1 (en) | 2016-12-22 | 2018-06-28 | Pierfrancesco Tassone | A monoclonal antibody targeting a unique sialoglycosilated cancer-associated epitope of cd43 |
| KR20240044544A (ko) | 2017-03-03 | 2024-04-04 | 씨젠 인크. | 글리칸-상호작용 화합물 및 사용 방법 |
| US10772971B2 (en) | 2017-06-22 | 2020-09-15 | Mersana Therpeutics, Inc. | Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates |
| JP2021510702A (ja) | 2018-01-12 | 2021-04-30 | プロリンクス エルエルシー | 相乗的がん治療 |
| AU2019262521B2 (en) | 2018-05-04 | 2024-04-18 | Tagworks Pharmaceuticals B.V. | Compounds comprising a linker for increasing transcyclooctene stability |
| CA3099419A1 (en) | 2018-05-04 | 2019-11-07 | Tagworks Pharmaceuticals B.V. | Tetrazines for high click conjugation yield in vivo and high click release yield |
| PE20210320A1 (es) | 2018-06-01 | 2021-02-16 | Novartis Ag | Moleculas de union contra bcma y usos de las mismas |
| CN113227127A (zh) | 2018-06-05 | 2021-08-06 | 伦敦大学国王学院 | 向胃肠系统递送酬载的btnl3/8导引构建体 |
| CA3117050A1 (en) | 2018-10-29 | 2020-05-07 | Mersana Therapeutics, Inc. | Cysteine engineered antibody-drug conjugates with peptide-containing linkers |
| KR20210099614A (ko) | 2018-12-04 | 2021-08-12 | 노파르티스 아게 | Cd3에 대한 결합 분자 및 이의 용도 |
| US12037378B2 (en) | 2019-05-21 | 2024-07-16 | Novartis Ag | Variant CD58 domains and uses thereof |
| UY38701A (es) | 2019-05-21 | 2020-12-31 | Novartis Ag | Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas |
| WO2020256546A1 (en) | 2019-06-17 | 2020-12-24 | Tagworks Pharmaceuticals B.V. | Compounds for fast and efficient click release |
| IL289094A (en) | 2019-06-17 | 2022-02-01 | Tagworks Pharmaceuticals B V | Tetrazines for increasing the speed and yield of the "click release" reaction |
| CN114585651A (zh) | 2019-08-08 | 2022-06-03 | 再生元制药公司 | 新型抗原结合分子形式 |
| AU2020379735A1 (en) | 2019-11-05 | 2022-05-26 | Regeneron Pharmaceuticals, Inc. | N-terminal SCFV multispecific binding molecules |
| CN115052663B (zh) | 2020-01-08 | 2026-06-09 | 辛瑟斯治疗股份有限公司 | Alk5抑制剂缀合物及其用途 |
| JP7859981B2 (ja) | 2020-03-06 | 2026-05-15 | ジーオー セラピューティクス，インコーポレイテッド | 抗グリコｃｄ４４抗体およびその使用 |
| WO2021195513A1 (en) | 2020-03-27 | 2021-09-30 | Novartis Ag | Bispecific combination therapy for treating proliferative diseases and autoimmune disorders |
| US11028132B1 (en) | 2020-04-07 | 2021-06-08 | Yitzhak Rosen | Half-life optimized linker composition |
| AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
| EP4301782A1 (en) | 2021-03-05 | 2024-01-10 | Go Therapeutics, Inc. | Anti-glyco-cd44 antibodies and their uses |
| JP2024531915A (ja) | 2021-08-05 | 2024-09-03 | ジーオー セラピューティクス，インコーポレイテッド | 抗グリコｍｕｃ抗体およびその使用 |
| WO2023034569A1 (en) | 2021-09-03 | 2023-03-09 | Go Therapeutics, Inc. | Anti-glyco-cmet antibodies and their uses |
| JP2024534910A (ja) | 2021-09-03 | 2024-09-26 | ジーオー セラピューティクス，インコーポレイテッド | 抗グリコｌａｍｐ１抗体およびその使用 |
| EP4399283A2 (en) | 2021-09-06 | 2024-07-17 | Veraxa Biotech GmbH | Novel aminoacyl-trna synthetase variants for genetic code expansion in eukaryotes |
| JP2024543916A (ja) | 2021-11-25 | 2024-11-26 | ヴェラクサ バイオテック ゲーエムベーハー | 遺伝暗号拡張を利用した部位特異的結合によって調製された改良された抗体ペイロード複合体（ａｐｃ） |
| DK4186529T3 (da) | 2021-11-25 | 2025-08-25 | Veraxa Biotech Gmbh | Forbedrede antistof-payload-konjugater (apc) fremstillet ved stedspecifik konjugering ved hjælp af genetisk kodeudvidelse |
| KR20240119102A (ko) | 2021-12-08 | 2024-08-06 | 유럽피안 몰레큘러 바이올로지 래보러토리 | 표적화 접합체의 제조를 위한 친수성 테트라진-관능화 페이로드 |
| EP4372000B1 (en) | 2022-02-15 | 2026-06-17 | Tagworks Pharmaceuticals B.V. | Masked il12 protein |
| KR20250049568A (ko) | 2022-07-15 | 2025-04-11 | 페온 테라퓨틱스 리미티드 | Cdcp1에 결합하는 항체 약물 접합체 및 이의 용도 |
| IL320221A (en) | 2022-10-12 | 2025-06-01 | Tagworks Pharmaceuticals B V | Strained bicyclo-nonanes |
| CN121002062A (zh) | 2023-01-13 | 2025-11-21 | 再生元制药公司 | Fgfr3结合分子及其使用方法 |
| CN120569216A (zh) | 2023-01-20 | 2025-08-29 | 巴斯夫欧洲公司 | 稳定型生物聚合物组合物、其制造和用途 |
| JP2026509291A (ja) | 2023-03-10 | 2026-03-17 | タグワークス ファーマシューティカルス ビー．ブイ． | 向上されたｔ－リンカーを有するトランス－シクロオクテン |
| WO2024258967A1 (en) | 2023-06-13 | 2024-12-19 | Synthis Therapeutics, Inc. | Anti-cd5 antibodies and their uses |
| EP4750750A1 (en) | 2023-07-27 | 2026-06-03 | Veraxa Biotech GmbH | Hydrophilic trans-cyclooctene (hytco) compounds, constructs and conjugates containing the same |
| CN122206462A (zh) | 2023-09-15 | 2026-06-12 | 巴斯夫欧洲公司 | 稳定型生物聚合物组合物、其制造和用途 |
| IL327670A (en) | 2023-10-11 | 2026-06-01 | Antikor Biopharma Ltd | Antibodies, conjugates, and uses thereof |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| WO2025174248A1 (en) | 2024-02-16 | 2025-08-21 | Tagworks Pharmaceuticals B.V. | Trans-cyclooctenes with "or gate" release |
| WO2025240335A1 (en) | 2024-05-13 | 2025-11-20 | Regeneron Pharmaceuticals, Inc. | Fgfr3 binding molecules and methods of use thereof |
| TW202617187A (zh) | 2024-08-22 | 2026-05-01 | 荷蘭商泰格沃克斯製藥有限公司 | 反-環辛烯調配物 |
| WO2026078060A1 (en) | 2024-10-08 | 2026-04-16 | Basf Se | Tocopherol alkoxylates for biopolymer stabilization |
| WO2026139575A1 (en) | 2024-12-23 | 2026-07-02 | Veraxa Biotech Gmbh | Novel tco-functionalized glycan engineered immunoglobulin molecules, novel tco-functionalized saccharide compounds for preparing the same, and novel antibody payload conjugates |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH26256A (en) | 1988-08-12 | 1992-04-01 | Fujisawa Pharmaceutical Co | Oxaspiro [2,5] octane derivative |
| US5811510A (en) | 1995-04-14 | 1998-09-22 | General Hospital Corporation | Biodegradable polyacetal polymers and methods for their formation and use |
| WO1998056372A1 (en) | 1997-06-09 | 1998-12-17 | Massachusetts Institute Of Technology | TYPE 2 METHIONINE AMINOPEPTIDASE (MetAP2) INHIBITORS AND USES THEROF |
| US20020103136A1 (en) | 1998-03-05 | 2002-08-01 | Dong-Mei Feng | Conjugates useful in the treatment of prostate cancer |
| WO1999061432A1 (en) | 1998-05-12 | 1999-12-02 | Biochem Pharma Inc. | Fumagillin analogs and their use as angiogenesis inhibitors |
| US6603812B1 (en) | 1998-08-17 | 2003-08-05 | Linear Technology Corporation | Hardware implementation of a decimating finite impulse response filter |
| AU2004270251B2 (en) * | 2003-09-05 | 2011-03-31 | The General Hospital Corporation | Polyacetal drug conjugates as release system |
| CN101155844A (zh) * | 2005-03-31 | 2008-04-02 | 阿帕医药有限公司 | 聚乙二醇-聚缩醛和聚乙二醇-聚缩醛-聚原酸酯接枝共聚物和药物组合物 |
| US20070019008A1 (en) | 2005-07-22 | 2007-01-25 | Xerox Corporation | Systems, methods, and programs for increasing print quality |
| BRPI0820229A2 (pt) * | 2007-11-28 | 2017-05-09 | A Stevenson Cheri | conjugados de análogos de fumagilina biodegradáveis biocompatíveis |
| EP2268315B1 (en) * | 2008-03-31 | 2019-07-31 | Freie Universität Berlin | Drug conjugates with polyglycerols |
-
2010
- 2010-05-27 JP JP2012513256A patent/JP2012528240A/ja active Pending
- 2010-05-27 US US12/789,047 patent/US8524214B2/en not_active Expired - Fee Related
- 2010-05-27 KR KR1020117031373A patent/KR20120057588A/ko not_active Withdrawn
- 2010-05-27 WO PCT/US2010/036413 patent/WO2010138719A1/en not_active Ceased
- 2010-05-27 EP EP10781215.8A patent/EP2435053B1/en not_active Not-in-force
- 2010-05-27 AU AU2010254013A patent/AU2010254013A1/en not_active Abandoned
- 2010-05-27 CA CA2762877A patent/CA2762877A1/en not_active Abandoned
- 2010-05-27 CN CN2010800236442A patent/CN102448469A/zh active Pending
- 2010-05-28 AR ARP100101862A patent/AR078510A1/es not_active Application Discontinuation
- 2010-05-28 TW TW099117180A patent/TW201102089A/zh unknown
-
2011
- 2011-11-13 IL IL216325A patent/IL216325A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012528240A (ja) | 可変速度放出リンカーを含むポリアル−薬物コンジュゲート | |
| JP2019513734A5 (enExample) | ||
| JP2014528466A5 (enExample) | ||
| CN108601952B (zh) | 雷公藤内酯的葡萄糖缀合物、类似物及其用途 | |
| JP2019512478A5 (enExample) | ||
| JP2020514300A5 (enExample) | ||
| JP2010521485A5 (enExample) | ||
| JP2014534200A5 (enExample) | ||
| RU2020123953A (ru) | Ингибирующие bcl-xl соединения, обладающие низкой клеточной проницаемостью, и конъюгаты антитело-лекарственное средство, включающие их | |
| JP2012502904A5 (enExample) | ||
| JP2018507197A5 (enExample) | ||
| JP2017504606A5 (enExample) | ||
| JP2016534990A5 (enExample) | ||
| JP2010509375A5 (enExample) | ||
| JP2012512898A5 (enExample) | ||
| JP2017503011A5 (enExample) | ||
| JP2019512492A (ja) | Ｐｅｇ化薬物リンカー及びその中間体を調製するためのプロセス | |
| JP2014515406A5 (enExample) | ||
| JP2013540114A5 (enExample) | ||
| JP2018058822A5 (enExample) | ||
| JP2013538213A5 (enExample) | ||
| JP2012513982A5 (enExample) | ||
| JP2019178158A5 (enExample) | ||
| JP2012512149A5 (enExample) | ||
| TWI439463B (zh) | 青蒿素之二聚衍生物及其在抗癌治療之應用 |